InsidersTradesSigma
Total declarations
Company
▲ Purchases (21 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
21
Disclosed sells
0
T+90 hit rate
24%
T+90 mean return
-18.2%
Across 21 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by EQUELS THOMAS K., Chairman & CEO. Officer active across 1 company, notably AIM ImmunoTech Inc.. Aggregated, 32 disclosures have been recorded. Breakdown: 21 buys · 0 sell. Total volume traded: €275k. Activity tracked since 16 July 2021. The latest transaction was disclosed on 12 June 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations32 total
103 shares@ US$8.70Common StockSEC:0001641172-25-015005:0
Ideal exit: 9 Mar 2026 (T+270)
1,968,504 shares@ US$0.02547.2% of flowCommon StockSEC:0001641172-25-005861:0
Ideal exit: 6 Jan 2026 (T+270)
41,000 shares@ US$0.0630.4% of flowCommon StockSEC:0001641172-25-002977:0
Ideal exit: 30 Dec 2025 (T+270)
50,000 shares@ US$0.13461.0% of flowCommon StockSEC:0001493152-25-009338:0
Ideal exit: 30 Nov 2025 (T+270)
44,000 shares@ US$0.1150.8% of flowCommon StockSEC:0001493152-25-009164:0
Ideal exit: 29 Nov 2025 (T+270)
83,334 shares@ US$0.121.5% of flowCommon StockSEC:0001493152-25-009003:0
Ideal exit: 29 Nov 2025 (T+270)
20,000 shares@ US$0.2120.7% of flowCommon StockSEC:0001493152-25-003058:0
Ideal exit: 18 Aug 2025 (T+270)
22,727 shares@ US$0.2060.7% of flowCommon StockSEC:0001493152-24-050757:0
Ideal exit: 14 Sept 2025 (T+270)
85,000 shares@ US$0.1992.6% of flowCommon StockSEC:0001493152-24-047094:0
Ideal exit: 17 Aug 2025 (T+270)
60,110 shares@ US$0.1831.7% of flowCommon StockSEC:0001493152-24-046952:0
Ideal exit: 17 Aug 2025 (T+270)
5,000 shares@ US$0.3030.2% of flowCommon StockSEC:0001493152-24-036837:0
Ideal exit: 13 Jun 2025 (T+270)
20,000 shares@ US$0.3080.9% of flowCommon StockSEC:0001493152-24-036364:0
Ideal exit: 10 Jun 2025 (T+270)
312,500 shares@ US$0.3214.7% of flowCommon StockSEC:0001493152-24-036076:0
377,358 shares@ US$0.26514.8% of flowCommon StockSEC:0001493152-24-031414:0
61,729 shares@ US$0.4053.8% of flowCommon StockSEC:0001493152-24-018030:0
Ideal exit: 31 Jan 2025 (T+270)
75,758 shares@ US$0.333.7% of flowCommon StockSEC:0001493152-24-010267:0
Ideal exit: 10 Dec 2024 (T+270)
33,861 shares@ US$0.4432.2% of flowCommon StockSEC:0001493152-23-042743:0
Ideal exit: 23 Aug 2024 (T+270)
22,676 shares@ US$0.4413.6% of flowCommon StockSEC:0001493152-23-034802:0
Ideal exit: 25 Jun 2024 (T+270)
8,222 shares@ US$0.6690.8% of flowCommon StockSEC:0001493152-23-030180:0
Ideal exit: 21 May 2024 (T+270)
14,993 shares@ US$0.6671.5% of flowCommon StockSEC:0001493152-23-030077:0
Ideal exit: 20 May 2024 (T+270)
16,950 shares@ US$0.591.4% of flowCommon StockSEC:0001493152-23-024767:0
Ideal exit: 12 Apr 2024 (T+270)
161,291 shares@ US$0.317.6% of flowCommon StockSEC:0001493152-23-000211:0
Ideal exit: 30 Sept 2023 (T+270)
32,895 shares@ US$0.764.0% of flowCommon StockSEC:0001450324-22-000004:0
49,020 shares@ US$1.021.18% mcap28.9% of flowCommon StockSEC:0001450324-22-000002:0
21,552 shares@ US$1.160.56% mcap13.7% of flowCommon StockSEC:0001450324-21-000013:0
25 of 32 declarations
About EQUELS THOMAS K.
Thomas K. Equels is an executive at AIM ImmunoTech Inc.
